Request Demo
Last update 15 Oct 2025
Povidone-Iodine
Last update 15 Oct 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Povidone Iodine, Povidone-iodine (JP17/USP), 原位凝胶缓释滴眼液 + [12] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Nov 1965), |
RegulationOrphan Drug (United States) |
Login to view timeline
Structure/Sequence
Molecular FormulaC6H9I2NO |
InChIKeyCPKVUHPKYQGHMW-UHFFFAOYSA-N |
CAS Registry25655-41-8 |
Related
317
Clinical Trials associated with Povidone-IodineNCT04200729
Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis
NCT06463678
A Phase II, Multi-center, Randomized, Masked, Parallel-Control Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% PVP-Iodine) Gel Forming Ophthalmic Solution in the Treatment of Fungal Keratitis
CTRI/2025/06/088791
Randomized controlled clinical study to evaluate the efficacy of Bala Taila Pichu and Povidone Ointment in the management of Shuddha Vrana. - NIL
100 Clinical Results associated with Povidone-Iodine
Login to view more data
100 Translational Medicine associated with Povidone-Iodine
Login to view more data
100 Patents (Medical) associated with Povidone-Iodine
Login to view more data
4,619
Literatures (Medical) associated with Povidone-Iodine31 Dec 2025JOURNAL OF OBSTETRICS AND GYNAECOLOGY
Comparison of sterile normal saline and 1% povidone-iodine for vaginal preparation in vesicovaginal fistula: a randomised trial
Article
Author: Xi, Zhijun ; Chen, Kaiyue ; Wang, Wei ; Che, Xinyan ; Ruan, Mingjian ; Wu, Shiliang ; Yang, Yang ; Huang, Yanbo ; Chen, Yuke ; Zhong, Lijun
BACKGROUND:
Vaginal preparation before transvaginal gynecological surgeries improves the success rate. However, there is no consensus on which agent is superior for transvaginal repair of vesicovaginal fistula (VVF). We aimed to compare irritation symptoms and antimicrobial function between sterile normal saline (SS) and 1% povidone-iodine (PI) for vaginal preparation in surgical repair of VVF.
METHODS:
This randomised, controlled trial was conducted on patients with VVF underwent transvaginal repair. Preoperative vaginal irrigation was randomly performed with either SS or 1% PI. The patients' self-reported symptoms questionnaires, including numerical rating scale (NRS) of pain, Indevus urgency severity scale (IUSS), and vaginal symptoms, tissue edoema degree and pathogenic microbiology were recorded.
RESULTS:
The study included 30 patients in the SS group and 31 patients in the PI group. After twice irrigations before surgery, compared with the PI group, the SS group had a similar count of bacterial species but a higher bacterial load (p = .079 and p = .033). The NRS of pain and IUSS in the SS group were lower than those in the PI group (p < .001). The SS group had less severe vaginal symptoms (p < .001) and tissue edoema (p < .001) than the PI group. The successful repair rates were 86.7% in the SS group and 83.9% in the PI group (p = .758). Patients with more severe urinary and vaginal symptoms had lower successful repair rates (92.3% vs. 72.7%, p = .047).
CONCLUSIONS:
SS is an effective vaginal preparation liquid for transvaginal repair of VVF with less irritation symptoms and acceptable antimicrobial function.
01 Dec 2025CHILDS NERVOUS SYSTEM
Povidone-iodine-induced scalp lesions in pediatric neurosurgery patients: a case series
Article
Author: Barkyoumb, David ; Tavakol, Sherwin A ; Desai, Virendra R ; Zhao, Xiaochun ; Bageac, Devin V ; Bowen, Ira E ; Stephens, Mark E
PURPOSE:
Povidone-iodine, or Betadine® (Atlantis Consumer Healthcare Inc., Bridgewater, NJ), is a commonly used agent for surgical site preparation. Although commonly used, it carries the risk of skin reactions, and multiple cases of intra-operative contact dermatitis and chemical burns have been reported. However, to our knowledge, there are currently no published cases of povidone-iodine-induced skin lesions in neurosurgical patients.
METHODS:
A single-center retrospective chart review was performed to identify patients who developed scalp lesions secondary to chemical toxicity following neurosurgical procedures between October 1, 2021, and June 30, 2024.
RESULTS:
Three patients were identified, ranging from 2.5 months to 14 years old. Two were positioned prone and the third in lateral decubitus. All patients' heads were supported by a horseshoe headrest covered with a gel pad and wrapped in a cotton roll. For two patients, Reston™ foam (3M©, St. Paul, MN) was added on the horseshoe. Surgical sites were prepped with isopropyl alcohol, Betadine®, and chlorohexidine. Two patients had their heads intermittently lifted throughout the procedure. Lesions were identified immediately after returning the patient to the supine position in the operating room and steadily improved over the course of one to five months with local wound care.
CONCLUSIONS:
Careful preparation of the surgical site is an essential step in the prevention of surgical site infections. However, caution should be exercised during skin preparation to avoid pooling of povidone-iodine around dependent regions. Additional steps, such as scheduled head elevations and pressure dispersion, should be taken to mitigate factors contributing to these lesions.
01 Nov 2025JOURNAL OF SURGICAL RESEARCH
Feasibility of Low-Volume Atomized Povidone-Iodine as a Peritoneal Antiseptic in Complicated Appendicitis
Article
Author: Dodd, Ashley C ; Grabowski, Julia E ; Lehane, Alison J ; Goldstein, Seth D ; Liesman, Daniel R ; Lautz, Timothy B ; Bates, Kelly R
INTRODUCTION:
Pediatric complicated appendicitis carries significant risk of abscess formation. Current surgical techniques for reduction of postoperative abscess include suction, irrigation with saline or dilute povidone-iodine, or drain placement. However, these approaches are not supported by high-quality evidence. This study aims to investigate the feasibility of administering low-volume atomized povidone-iodine (LVAP) as an antiseptic technique for complicated appendicitis.
MATERIALS AND METHODS:
A retrospective case-control study of pediatric complicated appendectomies was performed at a children's hospital from 2020 to 2024. Extent of perforation was characterized as contained infection versus uncontained infection with widespread peritonitis. LVAP comprised of 5-10 cc of finely misted, nondilute povidone-iodine applied to areas of peritoneal contamination using a customized hand-powered nozzle via a standard working 5 mm trocar over approximately 15 s. Treatment was recorded as LVAP versus standard practice (suction or saline irrigation). Clinical results were compared in a stratified matching analysis.
RESULTS:
A total of 25 patients underwent LVAP and 340 underwent standard practice. Following 2:1 matching, 50 standard practice controls were included. No adverse sequelae of LVAP were noted. No statistically significant difference was detected between abscess rates following LVAP versus standard practice (16% (4/25) versus 24% (12/50), P = 0.56), though no abscesses were seen following LVAP administration for contained infection.
CONCLUSIONS:
LVAP is a novel, feasible operative technique for complicated pediatric appendicitis. Though we were unable to demonstrate statistical significance, our observations of LVAP in reducing abscess rates for contained infection are promising. We are now able to estimate appropriate sample sizes needed to achieve sufficient power for a future study.
18
News (Medical) associated with Povidone-Iodine
100 Deals associated with Povidone-Iodine
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Pressure Ulcer | Japan | 01 Jul 1999 | |
| Skin Ulcer | Japan | 01 Jul 1999 | |
| Bacterial Infections and Mycoses | Australia | 07 Sep 1991 | |
| Burn infections | Australia | 07 Sep 1991 | |
| Chronic pharyngitis | Australia | 07 Sep 1991 | |
| Eye Diseases | United States | 17 Dec 1986 | |
| Disinfectants | Japan | - | 01 Nov 1965 |
| Burns | China | - | |
| Candidiasis, Vulvovaginal | China | - | |
| Hemorrhoids | China | - | |
| Skin Diseases, Infectious | China | - |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dental Plaque | Phase 3 | United States | 01 Oct 2007 | |
| Fungal keratitis | Phase 2 | - | 01 Aug 2026 | |
| Adenoviral Conjunctivitis | Phase 2 | India | 20 Feb 2023 | |
| Adenoviridae Infections | Phase 2 | India | 20 Feb 2023 | |
| acute bacterial conjunctivitis | Phase 2 | China | 05 Jan 2023 | |
| acute bacterial conjunctivitis | Phase 2 | China | 05 Jan 2023 | |
| Acute adenoviral follicular conjunctivitis | Phase 2 | China | 04 Jan 2022 | |
| Acute adenoviral follicular conjunctivitis | Phase 2 | China | 04 Jan 2022 | |
| Conjunctivitis | Phase 2 | United States | - | |
| COVID-19 | Preclinical | United States | 17 Sep 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 129 | (IVIEW-1201) | ceeippwfqc: P-Value = 0.0137 | - | 15 Jun 2025 | ||
(Ofloxacin Eye Drops) | |||||||
Phase 4 | 192 | (Treatment) | yjukdqjate(eifpvkqunz) = psddsugjxb nqzbeknwvx (igcthcwaih, uhnmvlwzvb - gfvavvhdfi) View more | - | 13 Nov 2024 | ||
0.9% NaCl Solution (Placebo) | yjukdqjate(eifpvkqunz) = hwaivmylwz nqzbeknwvx (igcthcwaih, sozygktaht - hzlxfqsgre) View more | ||||||
Phase 2 | 129 | woppfjkwpn(zpwjmrgyoy) = oderkdgxue cdeejajsmu (pmsygezvpf ) | Similar | 07 May 2024 | |||
woppfjkwpn(zpwjmrgyoy) = ouqgrdxylc cdeejajsmu (pmsygezvpf ) | |||||||
Not Applicable | - | Rectal betadine preparation | zrmptlqglb(pangglaphp) = xukqycccqx qusxailskj (tfxponvzwu ) View more | - | 01 May 2024 | ||
Phase 2 | 128 | 27% Ethanol plus essential oils (27% Ethanol Plus Essential Oils) | skoxncmqzz(efoizvsimo) = rlrgudymom lfbprxlnhh (rxfbulefgl, 34132.53) View more | - | 25 Mar 2024 | ||
0.075% Cetylpyridinium Chloride (0.075% Cetylpyridinium Chloride) | skoxncmqzz(efoizvsimo) = teyhmfluey lfbprxlnhh (rxfbulefgl, 8311.31) View more | ||||||
Phase 4 | 65 | secyzonqeq = avbjxbnbky jifjohmuyo (bufcsmdmfg, pklspwcuhu - etywydosfi) View more | - | 28 Jun 2023 | |||
Phase 4 | 1,638 | (10% Povidone-iodine (1% Free Iodine) in Purified Water) | mcsulibjne = mlyceajgnp wleipxxkym (rctfdsvkjw, mgltkeafgn - jjiqfqcwyy) View more | - | 31 Mar 2023 | ||
(4% Chlorhexidine Gluconate (CHG) in Purified Water) | mcsulibjne = vlvxnbxzty wleipxxkym (rctfdsvkjw, xljjszmheo - pnawdhsmjl) View more | ||||||
Not Applicable | - | mfnqhuwrdv(mqifazggzk) = four serious complications were noticed in Group B (19%) mpgcuwglaq (bvzivtctek ) View more | Positive | 04 Sep 2022 | |||
Not Applicable | 932 | Chlorhexidine - Isopropyl alcohol (Chlorhexidine - Isopropyl Alcohol) | qowiblhtic = lllzpoaqgq pukkvgtnme (nuejihxwzl, ojctvpuccv - qcgknjzhlf) View more | - | 21 Jul 2022 | ||
(Povidone-Iodine Scrub and Paint) | qowiblhtic = zpnnuqdkmr pukkvgtnme (nuejihxwzl, crzghwcvgm - kwevvmfvku) View more | ||||||
Phase 1/2 | 47 | Isotonic saline 0.9% (Isotonic Saline 0.9%) | keboixrbzr(cbchgsgkff) = kvfkphegdr gjktdsfeqr (rjpkczwgod, 6.83) View more | - | 21 Oct 2021 | ||
(Povidone-Iodine 0.5%) | keboixrbzr(cbchgsgkff) = etauoodnjq gjktdsfeqr (rjpkczwgod, 4.86) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free